Mechanisms and consequences of phagocyte adhesion to endothelium

Annals of Medicine

Volumn 31, Issue 3, 1999, Pages 156-165

  Repo, Heikki ^a   Harlan, John M ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adhesion; Integrin; Molecules; Monocyte; Neutrophil; Selectin

Indexed keywords

ANTIBODY; CD11B ANTIGEN; CELL ADHESION MOLECULE; INTEGRIN; MONOCLONAL ANTIBODY; SELECTIN;

ANTIGEN EXPRESSION; BLOOD VESSEL INJURY; CELL ACTIVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE ADHERENCE; MULTICENTER STUDY; PHAGOCYTE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TISSUE INJURY; VASCULAR ENDOTHELIUM;

EID: 0032972640     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899909115974     Document Type: Review

References (99)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
2. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 1994; 45: 361-78.
3. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991; 88: 4651-5.
4. Sata M, Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4: 415-20.
5. Preece G, Murphy G, Ager A. Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem 1996; 271: 11634-40.
6. Yarema KJ, Bertozzi CR. Chemical approaches to glycobiology and emerging carbohydrate-based therapeutic agents. Curr Opin Chem Biol 1998; 2: 49-61.
7. Lefer AM. Selectins: vital vasculotropic vectors involved in vascular remodeling. Circulation 1997; 96: 3258-60.
8. Frenette PS, Wagner DD. Insights into selectin function from knockout mice. Thromb Haemost 1997; 78: 60-4.
9. Varki A. Selectin ligands: will the real ones please stand up? J Clin Invest 1997; 99: 158-62.
10. Diamond MS, Springer TA. The dynamic regulation of integrin adhesiveness. Curr Biol 1994; 4: 506-17.
11. Gahmberg CG, Tolvanen M, Kotovuori P. Leukocyte adhesion. Structure and function of human beta2-integrins and their cellular ligands. Eur J Biochem 1997; 245: 215-32.
12. Hughes PE, Pfaff M. Integrin affinity modulation. Cell Biol 1998; 8: 359-64.
13. Bazzoni G, Hemler ME. Are changes in integrin affinity and conformation overemphasized? Trends Biochem Sci 1998; 23: 30-4.
14. Xie J, Li R, Kotovuori P, Vermot-Desroches C, Wijdenes J, Arnaout MA, et al. Intercellular adhesion molecule-2 (CD102) binds to the leukocyte integrin CD11b/CD18 through the A domain. J Immunol 1995; 155: 3619-28.
15. Issekutz AC, Rowter D, Springer TA. Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligand in neutrophil transendothelial migration. J Leukoc Biol 1999; 65: 117-26.
16. Repo H, Rochon YP, Schwartz BR, Sharar SR, Winn RK, Harlan JM. Binding of human peripheral blood polymorphonuclear leukocytes to E-selectin (CD62E) does not promote their activation. J Immunol 1997; 159: 943-51.
17. Newman PJ. The biology of PECAM-1. J Clin Invest 1997; 99: 3-7.
18. Duncan GS, Andrew DP, Takimoto H, Kaufman SA, Yoshida H, Spellberg J, et al. Genetic evidence for functional redundancy of platelet/endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions. J Immunol 1999; 162: 3022-30.
19. Ware JA, Heistad DD. Platelet-endothelium interactions. N Engl J Med 1993; 328: 628-35.
20. Kuijper PH, Gallardo Torres HI, van der Linden JA, Lammers JW, Sixma JJ, Koenderman L, et al. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood 1996; 87: 3271-81.
21. Kuijper PH, Gallardo Torres HI, Lammers J-WJ, Sixma JJ, Koenderman L, Zwaginga JJ. Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions. Blood 1997; 89: 166-75.
22. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085-93.
23. Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997; 89: 1270-8.
24. Ostrovsky L, King AJ, Bond S, Mitchell D, Lorant DE, Zimmerman GA, et al. A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process. Blood 1998; 91: 3028-36.
25. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51.
26. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991; 65: 467-73.
27. Czervionke RL, Hoak JC, Fry GL. Effect of aspirin on thrombin-induced adherence of platelets to cultured cells from the blood vessel wall. J Clin Invest 1978; 62: 847-56.
28. Fry GL, Czervionke RL, Hoak JC, Smith JB, Haycraft DL. Platelet adherence to cultured vascular cells: influence of prostacyclin (PGI2). Blood 1980; 55: 271-5.
29. Kaplan JE, Moon DG, Weston LK, Minnear FL, Del Vecchio PJ, Shepard JM, et al. Platelets adhere to thrombin-treated endothelial cells in vitro. Am J Physiol 1989; 257: H423-33.
30. Tloti MA, Moon DG, Weston LK, Kaplan JE. Effect of 13-hydroxy-octadeca-9,11-dienoic acid (13-HODE) on thrombin induced platelet adherence to endothelial cells in vitro. Thromb Res 1991; 62: 305-17.
31. Diacovo TG, Puri KD, Warnock RA, Springer TA, von Andrian UH. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996; 273: 252-5.
32. Li JM, Podolsky RS, Rohrer MJ, Cutler BS, Massie MT, Barnard MR, et al. Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa. J Surg Res 1996; 61: 543-8.
33. Manduteanu I, Calb M, Lupu C, Simionescu N, Simionescu M. Increased adhesion of human diabetic platelets to cultured valvular endothelial cells. J Submicrosc Cytol Pathol 1992; 24: 539-47.
34. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A 1995; 92: 7450-4.
35. Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, Krombach F, et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998; 92: 507-15.
36. Etingin OR, Silverstein RL, Hajjar DP. Von Willebrand factor mediates platelet adhesion to virally infected endothelial cells. Proc Natl Acad Sci U S A 1993; 90: 5153-6.
37. Buchanan MR, Bertomeu MC, Haas TA, Orr FW, Eltringham-Smith LL. Localization of 13-hydroxyoctadecadienoic acid and the vitronectin receptor in human endothelial cells and endothelial cell/platelet interactions in vitro. Blood 1993; 81: 3303-12.
38. Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 1990; 8: 511-8.
39. Rosenblum WI, Nelson GH, Wormley B, Werner P, Wang J, Shih CCY. Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo. Stroke 1996; 27: 709-11.
40. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIb alpha. J Exp Med 1998; 187: 329-39.
41. Hawrylowicz CM, Howells GL, Feldmann M. Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med 1991; 174: 785-90.
42. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 1993; 81: 2492-5.
43. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
44. Hynes RO, Wagner DD. Genetic manipulation of vascular adhesion molecules in mice. J Clin Invest 1996; 98: 2193-5.
45. Hayward AR, Harvey BA, Leonard J, Greenwood MC, Wood CB, Soothill JF. Delayed separation of the umbilical cord, wide-spread infections, and defective neutrophil mobility. Lancet 1979; 1: 1099-101.
46. Lipnick RN, Iliopoulos A, Salata K, Hershey J, Melnick D, Tsokos GC. Leukocyte adhesion deficiency: report of a case and review of the literature. Clin Exp Rheumatol 1996; 14: 95-8.
47. Anderson DC. Leucocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med 1987; 38: 175-94.
48. Arnaout MA. Leucocyte adhesion molecules deficiency: its structural basis, pathophysiology and implications for modulating the inflammatory response. Immunol Rev 1990; 114: 145-80.
49. Le Deist F, Blanche S, Keable H, Gaud C, Pham H, Descamp-Latscha B, et al. Successful HLA non-identical bone marrow transplantation in three patients with the leukocyte adhesion deficiency. Blood 1989; 74: 512-6.
50. Bauer TR, Schwartz BR, Conrad Liles W, Ochs HD, Hickstein DD. Retroviral-mediated gene transfer of the leukocyte integrin CD18 into peripheral blood CD34+ cells derived from a patient with leukocyte adhesion deficiency type 1. Blood 1998; 91: 1520-6.
51. Kuijpers TW, van Lier RA, Hamann D, de Boer M, Thung LY, Weening RS, et al. Leukocyte adhesion deficiency type 1 (LAD-1)/Variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins. J Clin Invest 1997; 100: 1725-33.
52. Hogg N, Stewart MP, Scarth SL, Newton R, Shaw JM, Law SK, et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest 1999; 103: 97-106.
53. Etzioni A, Frydman M, Pollack S, Avidor I, Phillips ML, Paulson JC, et al. Recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med 1992; 327: 1789-92.
54. von Andrian UH, Berger EM, Ramezani L, Chambers JD, Ochs HD, Harlan JM, et al. In vivo behavior of neutrophils from two patints with distinct inherited leukocyte adhesion deficiency syndromes. J Clin Invest 1993; 91: 2893-7.
55. Phillips LM, Schwartz BR, Etzioni A, Bayer R, Ochs HD, Paulson JC, et al. Neutrophil adhesion in leukocyte adhesion deficiency syndrome type 2. J Clin Invest 1995; 93: 2898-906.
56. Cornejo CJ, Winn RK, Harlan JM. Anti-adhesion therapy. Adv Pharmacol 1997; 39: 99-142.
57. Menger MD, Vollmar B. Adhesion molecules as determinants of disease: from molecular biology to surgical research. Br J Surg 1996; 83: 588-601.
58. Barnes PJ, Karin M. Nuclear factor-kappaB; a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
59. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein Iib/IIIa integrin blockade. Circulation 1998; 98: 2629-35.
60. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.
61. Sligh JE Jr, Ballantyne CM, Rich SS, Hawkins HK, Smith CV, Bradley A, et al. Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1993; 90: 8529-33.
62. Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS, et al. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med 1994; 180: 95-109.
63. Argenbright LW, Letts LG, Rothlein R. Monoclonal antibodies to the leukocyte membrane CD18 glycoprotein complex and to intercellular adhesion molecule-1 inhibit leukocyte-endothelial adhesion in rabbits. J Leukoc Biol 1991; 49: 253-7.
64. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995; 45: 815-9.
65. Haug CE, Colvin RB, Delmonico FL, Auchincloss H Jr, Tolkoff-Rubin N, Preffer FI, et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993; 55: 766-72
66. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 37: 992-9.
67. Vuorte J, Lindsberg P, Kaste M, Meri S, Jansson SE, Rothlein R, et al. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol 1999; 162; 2353-7.
68. Arnaout MA, Hakim RM, Todd RF 3rd, Dana N, Colten HR. Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 1985; 312: 457-62.
69. Scherman DG. The Enlimomab Acute Stroke Trial: final results (abstract). Neurology 1997; 48: A270.
70. Bennett CF, Condon T, Grimm S, Chan H, Chiang MY. Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides. J Immunol 1994; 152: 3530-40.
71. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-42.
72. Vedder NB, Winn RK, Rice CL, Chi EY, Arfors KE, Harlan JM. Inhibition of leukocyte adherence by anti-CD18 monoclonal antibody attenuates reperfusion injury in the rabbit ear. Proc Natl Acad Sci U S A 1990; 87: 2643-6.
73. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991; 88: 1237-43.
74. Winn RK, Ramamoorthy C, Vedder NB, Sharar SR, Harlan JM. Leukocyte-endothelial cell interactions in ischemia-reperfusion injury. Ann N Y Acad Sci 1997; 832: 311-21.
75. Botha AJ, Moore FA, Moore EE, Sauaia A, Banerjee A, Peterson VM. Early neutrophil sequestration after injury: a pathogenic mechanism for multiple organ failure. J Trauma 1995; 39: 411-7.
76. Sharar SR, Winn RK, Murry CE, Harlan JM, Rice CL. A CD18 monoclonal antibody increases the incidence and severity of subcutaneous abscess formation after high-dose Staphylococcus aureus injection in rabbits. Surgery 1991; 110: 213-9.
77. Vedder N, Harlan J, Winn R, Heckbert S, Maier R, Hudson L, et al. Pilot phase 2 clinical trial of a humanized CD11/CD18 monoclonal antibody in hemorrhagic shock (abstract). Shock 1997; 7: A659.
78. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24: 163-72.
79. Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A, et al. The Italian SEPSIS study: preliminary results on the incidence and evoultion of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 1995; 21: S244-9.
80. Heckbert SR, Vedder NB, Hoffman W, Hudson LD, Jurkowich GJ, Copass MK, et al. Outcome after hemorrhagic shock in trauma patients. J Trauma 1998; 45: 545-9.
81. Calafat J, Kuijpers TW, Janssen H, Borregaard N, Verhoeven JA, Roos D. Evidence for small intracellular vesicles in human blood phagocytes containing cytochrome b558 and the adhesion molecule CD11b/CD18. Blood 1993; 81: 3122-9.
82. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hinds R, Smith BR. Cardiopulmonary bypass induces leukocyteplatelet adhesion. Blood 1992; 79: 1201-5.
83. Repo H, Jansson SE, Leirisalo-Repo M. Flow cytometric determination of CD11b upregulation in vivo. J Immunol Methods 1993; 164: 193-202.
84. Lin RY, Astiz ME, Saxon JC, Rackow EC. Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest 1993; 104: 847-53.
85. Lin RY, Astiz ME, Saxon JC, Saha DC, Rackow ED. Relationship between plasma cytokine concentrations and leukocyte functional antigen expression in patients with sepsis. Crit Care Med 1994; 22: 1595-1602.
86. Nelson RD, Hasslen SR, Ahrenholz DH, Haus E, Solem LD. Influence of minor thermal injury on expression of complement receptor CR3 on human neutrophils. Am J Pathol 1986; 125: 563-70.
87. Takala AJ, Jousela IT, Takkunen OS, Jansson SE, Kyosola KT, Olkkola KT, et al. Time course of beta2-integrin CD11b/CD18 (Mac-1, alpha Mbeta 2) upregulation on neutrophils and monocytes after coronary artery bypass grafting. Scand J Thorac Cardiovasc Surg 1996; 30: 141-8.
88. Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996: 61: 1714-20.
89. Takala A, Jousela I, Olkkola KT, Jansson SE, Leirisalo-Repo M, Takkunen O, et al. Systemic inflammatory response syndrome without systemic inflammation in acutely ill patients admitted to hospital in a medical emergency. Clin Sci 1999; 96: 287-95.
90. Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 1995; 274: 58-65.
91. Thiel M, Imendörffer S, Chouker A, Groh J, Briegel J, Anthuber M, et al. Expression of adhesion molecules on circulating polymorphonuclear leukocytes during orthotopic liver transplantation. Hepatology 1998; 28: 1538-50.
92. Inoue T, Sakai Y, Mooraka S, Hayashi T, Takayanagi K, Takabatake Y. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996; 28: 1127-33.
93. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol 1996; 28: 345-53.
94. Damas P, Canivet JL, de Groote D, Vrindts Y, Albert Y, Franchimont P, et al. Sepsis and serum cytokine concentrations. Crit Care Med 1997; 25: 405-12.
95. Grau GE, Maennel DN. TNF inhibition and sepsis - Sounding a cautionary note. Nat Med 1997; 3: 1193-5.
96. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23: 1294-303.
97. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-9.
98. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprednisolone therapy on unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998; 280: 159-65.
99. Döcke WD, Randow F, Syrbe U, Carson SJ, Umberger RA, Kelso T, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3: 678-81.